5.3. Laboratory Measurement (continued)
The best tests for assessing the anticoagulant activity of dabigatran include the dilute thrombin time, ecarin clotting time, and ecarin chromogenic assay (see Table 2) (18,19). These tests correlate closely with dabigatran levels measured by the reference standard method, liquid chromatography-tandem mass spectrometry. Unfortunately, these assays are not widely available, particularly on an emergent basis (18,19). In their absence, the thrombin time (TT) and aPTT may be used for qualitative assessment (see Table 3). The TT is exquisitely sensitive to dabigatran, even at very low drug concentrations. Thus, a normal TT excludes clinically relevant dabigatran levels, but a prolonged TT does not discriminate between clinically important and insignificant drug concentrations. All laboratories that do not offer an around-theclock assay for dabigatran quantification should be encouraged to offer the TT for rapid exclusion of clinically significant dabigatran levels. A prolonged aPTT suggests the presence of on-therapy or above on-therapy levels of dabigatran. However, a normal aPTT does not exclude the presence of on-therapy levels, especially when a relatively insensitive aPTT reagent is used (16,18,19)
The preferred test for assessing the anticoagulant activity of apixaban, edoxaban, and rivaroxaban is a chromogenic anti-Xa assay (see Table 2) (18,19). When the assay is calibrated with the drug of interest, the results correlate closely with plasma drug levels measured by liquid chromatography-tandem mass spectrometry. When the assay is calibrated with a low-molecular-weight heparin standard, it can be useful for excluding clinically important levels of drug, but not for quantitation. If an anti-Xa assay is not available, the PT may be useful for qualitative assessment of edoxaban and rivaroxaban. A prolonged PT suggests on-therapy or above on-therapy levels for these agents. However, depending on the sensitivity of the PT reagent, a normal PT may not exclude on-therapy levels (18,19). The PT and aPTT are insensitive to apixaban. A prolonged PT suggests the presence of clinically important apixaban levels, but a normal PT and aPTT do not exclude on-therapy or even above on-therapy levels of the drug (18–20).
Follow Tom On:
Categories
-
Recent Posts
- “Ep 161 Red Flag Headaches: General Approach and Cervical Artery Dissections” From Emergency Medicine Cases With Links To Additional Resources
- “POCUS For Gout” From MetroHealth Emergency Ultrasound
- Links To And Excerpts From The Five Es Of Cardiac POCUS: Introduction
- Links To And Excerpts From “A practical approach to goal-directed echocardiography in the critical care setting”
- Link To The Outstanding Resource “Cardiac Ultrasound (Echocardiography) Made Easy: Step-By-Step Guide” From POCUS 101
- YouTube Video From ACCP Chest “Advanced Critical Care Echocardiography – Complete Exam”
- Links To And Excerpts From “A review: Mechanism of action of antiviral drugs”
- YouTube Video: “Bedside Testicular Ultrasound” From MetroHealth Emergency Ultrasound
- Links To GastricUltrasound
- Gastric POCUS From MetroHealth Emergency Ultrasound
- Links To And Excerpts From “Guidelines for Evaluating New Fever in Adult Patients in the ICU”
- Link To And Excerpts From StatPearls’ Acute Inflammatory Response
- Link To And Excerpts From StatPearls’ Interleukin
- Links To And Excerpts From “First-degree family history of prostate cancer is associated the risk of breast cancer and ovarian cancer”
- Link To And Excerpts From StatPearls’ “Interferon”
- Linking To And Embedding The CDC’s “Does Your Family Health History Put You At Risk?”
- Linking To And Embedding CDC’s “Does Breast Or Ovarian Cancer Run In Your Family?”
- Links To And Excerpts From “Imaging Modalities for Evaluation of Intestinal Obstruction”
- Link To And Excerpts From StatPearls’ “Syncope”
- Excellent New York Times Article On Getting Older 04-08-2024
- Link To And Excerpts From StatPearls “Cardiac Syncope”
- “Cardiogenic Syncope” By Dr. Amal Mattu
- Reviewing The 5 Es Of Cardiac Pocus: Entrance With A Link To POCUS For Jugular Venous Pressure
- Reviewing The 5 Es Of Cardiac Pocus: Exit
- A Podcasting Example: Thriving With Cheryl Jones
- Reviewing The 5 Es Of Cardiac Pocus: Equality
- Reviewing The Five Es Of Cardiac POCUS: Ejection
- Reviewing The Five Es Of Cardiac POCUS: Effusion
- Links To And Excerpts From “Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview”
- How To Do Cardiac POCUS: “Point of Care Ultrasound (POCUS) – Cardiac”